---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-068948"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2024-06-06T23:59:59+00:00"
generated_at: "2026-06-01T05:57:21.612846+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Replimune reports positive IGNYTE primary analysis: ORR 33.6% in anti-PD1 failed melanoma; BLA submission planned 2H2024

## Summary
- Primary analysis shows ORR 33.6% (modified RECIST 1.1) and 32.9% (RECIST 1.1) by independent central review; all responses >6 months, median DOR >35 months.
- BLA submission intended for 2H2024; confirmatory IGNYTE-3 trial first patient expected Q3 2024.
- Safety: predominantly Grade 1-2 constitutional events; no Grade 5 events; low incidence of Grade 3-4 incidents.
- Data improves on investigator-assessed results presented at ASCO 2024; FDA-requested RECIST 1.1 analysis included.

## SEC filing metadata
- accession: 0001104659-24-068948
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2024-06-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465924068948/0001104659-24-068948-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465924068948/tm2416613d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-068948
- JSON: https://secwatch.observer/filing/0001104659-24-068948.json
- Plain text: https://secwatch.observer/filing/0001104659-24-068948.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.